Date:5/2/2011

CR).  At this session, presenters from Novartis and Stanford described the impact of Caliper's tissue and in vivo molecular imaging systems on translational medicine and personalized cancer treatment, and presenters from Caliper described how Caliper's disruptive technologies enable personalized medicine and oncology research.
Approximately 250 oncology researchers attended this well-received session.

Caliper completed Phase IIb primary screening under CDAS' EPA ToxCast contract and was awarded $3.1 million of new EPA task orders to fund the next stages of ToxCast work.   The Phase I ToxCast results and initial conclusions regarding toxicology correlations were published in the scientific journal Toxicology in March 2011.  ToxCast data and resulting predictive models are being used by Caliper to identify possible safety liabilities of environmental chemicals, cosmetic ingredients, and/or pharmaceuticals, and to identify biomarkers for potential rescue of drug candidates through personalized medicine approaches.

Caliper formed a research collaboration with Denver-based Catholic Health Initiatives to provide Caliper with access to human tumor samples to develop improved methods for evaluating and predicting the efficacy of new cancer drugs and for providing enhanced solutions for personalized medicine and patient stratification in oncology.  

Kevin Hrusovsky, Caliper President and CEO, was an invited speaker and panel participant at the Massachusetts Biotechnology Council's annual conference on the topic of "Translational Medicine – Genomics, Clinical Implementation, Pharmaco-Kinetics, and Prospective Healthcare" on March 21st.  His talk highlighted the role of technology companies working with research hospitals, pharma and academia in being able to accelerate personalized medicine.  The panel included thought leaders from Pfizer, Mass General Hospital, The Spinal Muscular Atrophy Foundation and Co
'/>"/>

SOURCE Caliper Life Sciences, Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10
Related medicine technology :

1. Caliper Life Sciences to Present at the 36th Annual Deutsche Bank Health Care Conference
2. Caliper Life Sciences First Quarter Results Conference Call Notice
3. Caliper Life Sciences Announces Date and Location of its 2011 Annual Meeting of Stockholders
4. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
5. Caliper Life Sciences and HistoRx to Provide Integrated Solutions for Superior Protein Quantification of Biomarkers in Tissue
6. Analysis of Calipers Phase I EPA ToxCast™ Data Published in Leading Scientific Journal
7. Caliper and Covaris Establish Co-Marketing Agreement to Simplify Next Generation Sequencing
8. Caliper Life Sciences Fourth Quarter and Fiscal Year 2010 Financial Results Conference Call Notice
9. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
10. Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols
11. Caliper and Seegene Partner to Provide Innovative Multiplex Molecular Diagnostics Products